Shiotani Akiko, Uedo Noriya, Iishi Hiroyasu, Tatsuta Masaharu, Ishiguro Shingo, Nakae Yukinori, Kamada Tomoari, Haruma Ken, Merchant Juanita L
Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan.
Int J Cancer. 2007 Sep 15;121(6):1182-9. doi: 10.1002/ijc.22835.
Loss of Sonic Hedgehog (Shh) and aberrant CDX2 expression are early changes correlating with the presence of intestinal metaplasia that occur in the gastric mucosa prior to neoplastic transformation. The aim of this study was to compare the improvement in corpus gastritis with Shh and CDX2 expression after H. pylori eradication between subjects at high risk for gastric cancer and controls. The usefulness of serum pepsinogen levels as a predictor of resolved corpus gastritis was also examined. Seventy patients with endoscopic resection for early gastric cancer and 30 controls were studied. Expression of Shh and CDX2 were evaluated by immunostaining. Serum levels of pepsinogen I before eradication in the patients scored as having improvement of corpus atrophy were significantly higher than in the patients without improvement (<0.01). Residual inflammation at the corpus lesser curve was more frequently detected in the cancer group than in the controls (OR 4.6 95% C.I. 1.6-13.5) and in the mucosa with incomplete intestinal metaplasia rather than in those without incomplete intestinal metaplasia (OR 7.6 95% C.I. 2.4-24.3). Atrophy, expression of Shh and CDX2 at the corpus lesser curve significantly improved in mucosa without incomplete intestinal metaplasia (p < 0.01), but not in mucosa with incomplete intestinal metaplasia. In conclusion, H. pylori eradication prior to development of incomplete intestinal metaplasia improves corpus gastritis and may prevent gastric cancer. Pepsinogen I may be a useful marker in patients with a residual higher risk of gastric cancer after H. pylori eradication.
音猬因子(Shh)缺失和CDX2异常表达是与胃黏膜肿瘤转化前发生的肠化生相关的早期变化。本研究的目的是比较胃癌高危人群和对照组在根除幽门螺杆菌后胃体胃炎伴Shh和CDX2表达的改善情况。还研究了血清胃蛋白酶原水平作为胃体胃炎缓解预测指标的有效性。对70例早期胃癌内镜切除术患者和30例对照进行了研究。通过免疫染色评估Shh和CDX2的表达。在评分显示胃体萎缩有所改善的患者中,根除前胃蛋白酶原I的血清水平显著高于未改善的患者(<0.01)。癌组胃体小弯处的残余炎症比对照组更常见(比值比4.6,95%置信区间1.6 - 13.5),且在伴有不完全肠化生的黏膜中比在无不完全肠化生的黏膜中更常见(比值比7.6,95%置信区间2.4 - 24.3)。在无不完全肠化生的黏膜中,胃体小弯处的萎缩、Shh和CDX2表达显著改善(p < 0.01),但在伴有不完全肠化生的黏膜中未改善。总之,在不完全肠化生发生之前根除幽门螺杆菌可改善胃体胃炎,并可能预防胃癌。胃蛋白酶原I可能是根除幽门螺杆菌后仍有较高胃癌风险患者的有用标志物。